Your session is about to expire
← Back to Search
Other
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg for Obesity
Phase 2
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomisation (week 24) to end of treatment (week 40)
Summary
This trial is testing a new weight loss medicine where participants receive either a combination of two medicines or one medicine alone. The medicine is given through regular injections using a pre-filled pen. The study targets individuals looking to lose weight, with specific guidelines for women regarding pregnancy and contraception. One of the medicines has been shown to induce significant weight loss in individuals with obesity or overweight, and it is approved for chronic weight management.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from randomisation (week 24) to end of treatment (week 40)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomisation (week 24) to end of treatment (week 40)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Part 1: Number of treatment-emergent adverse events (TEAEs)
Part 2: Change in body weight
Secondary study objectives
Part 2: Change in HbA1c
Part 2: Change in fasting insulin
Part 2: Change in fasting plasma glucose
+9 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Semaglutide 2.4 mg and NNC0165-1875 2.0 mgExperimental Treatment1 Intervention
Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
Group II: Semaglutide 2.4 mg and NNC0165-1875 1.0 mgExperimental Treatment1 Intervention
Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
Group III: Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)Placebo Group1 Intervention
Participants will receive placebo as an add on to semaglutide 2.4 mg.
Group IV: Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)Placebo Group1 Intervention
Participants will receive placebo as an add on to semaglutide 2.4 mg.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
2021
Completed Phase 2
~120
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
2021
Completed Phase 2
~120
Find a Location
Who is running the clinical trial?
Novo Nordisk A/SLead Sponsor
1,549 Previous Clinical Trials
2,443,912 Total Patients Enrolled
152 Trials studying Obesity
143,375 Patients Enrolled for Obesity
Clinical Transparency (dept. 1452)Study DirectorNovo Nordisk A/S
57 Previous Clinical Trials
45,219 Total Patients Enrolled
10 Trials studying Obesity
18,258 Patients Enrolled for Obesity
Share this study with friends
Copy Link
Messenger